Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
2015 · Science · 7,818 citations
https://doi.org/10.1126/science.aaa1348
R
Roberta Zappasodi
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
228
Papers
15.2K
Citations
36
h-index
53
i10-index
Roberta Zappasodi is an academic researcher from Cornell University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & CAR-T cell therapy research. The author has an h-index of 36, co-authored 194 publications.
ORCID: 0000-0002-7031-6671Papers by this author
worksUptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors
2021 · Immunity · 673 citations
https://doi.org/10.1016/j.immuni.2021.05.003
Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
2020 · Nature Communications · 418 citations
https://doi.org/10.1038/s41467-020-17750-z
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
2021 · Nature · 381 citations
https://doi.org/10.1038/s41586-021-03326-4
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
2018 · Cancer Cell · 113 citations
https://doi.org/10.1016/j.ccell.2018.09.008
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab
2014 · Cancer Research · 81 citations
https://doi.org/10.1158/0008-5472.can-14-0983
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat